Don't Miss: Best Chance to Access Midcap Stocks Research at 80% OFF
Here is the latest financial fact sheet of PIRAMAL PHARMA. For more details, see the PIRAMAL PHARMA quarterly results and PIRAMAL PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -1.3 |
No. of shares | m | 1,322.95 |
1 Week | % | -1.1 |
1 Month | % | 19.8 |
1 Year | % | 100.5 |
52 week H/L | Rs | 149.0/67.9 |
No. of Mths Year Ending |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
PIRAMAL PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | 202 | |||
Low | Rs | NA | NA | 63 | |||
Sales per share (Unadj.) | Rs | 63.5 | 55.3 | 59.3 | |||
Earnings per share (Unadj.) | Rs | 8.4 | 3.2 | -1.6 | |||
Diluted earnings per share | Rs | 6.3 | 2.8 | -1.4 | |||
Cash flow per share (Unadj.) | Rs | 13.9 | 8.1 | 4.1 | |||
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | |||
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | |||
Avg Dividend yield | % | 0 | 0 | 0 | |||
Book value per share (Unadj.) | Rs | 56.4 | 56.5 | 56.8 | |||
Adj. book value per share | Rs | 42.4 | 50.6 | 51.2 | |||
Shares outstanding (eoy) | m | 994.60 | 1,185.91 | 1,193.32 | |||
Price / Sales ratio | x | 0 | 0 | 2.2 | |||
Avg P/E ratio | x | 0 | 0 | -84.8 | |||
P/CF ratio (eoy) | x | 0 | 0 | 32.2 | |||
Price / Book Value ratio | x | 0 | 0 | 2.3 | |||
Dividend payout | % | 0 | 0 | 0 | |||
Avg Mkt Cap | Rs m | 0 | 0 | 158,073 | |||
Total wages/salary | Rs m | 14,677 | 15,888 | 18,964 |
PIRAMAL PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 63,149 | 65,591 | 70,816 | |||
Other income | Rs m | 1,641 | 2,758 | 2,251 | |||
Total revenues | Rs m | 64,790 | 68,349 | 73,067 | |||
Gross profit | Rs m | 14,934 | 9,936 | 6,756 | |||
Depreciation | Rs m | 5,450 | 5,862 | 6,767 | |||
Interest | Rs m | 1,635 | 1,983 | 3,442 | |||
Profit before tax | Rs m | 9,491 | 4,850 | -1,202 | |||
Minority Interest | Rs m | 0 | 0 | 0 | |||
Prior Period Items | Rs m | 0 | 0 | 0 | |||
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | |||
Tax | Rs m | 1,140 | 1,090 | 663 | |||
Profit after tax | Rs m | 8,350 | 3,760 | -1,865 | |||
Gross profit margin | % | 23.6 | 15.1 | 9.5 | |||
Effective tax rate | % | 12.0 | 22.5 | -55.2 | |||
Net profit margin | % | 13.2 | 5.7 | -2.6 |
PIRAMAL PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 37,491 | 41,519 | 48,435 | |||
Current liabilities | Rs m | 25,907 | 31,180 | 38,510 | |||
Net working cap to sales | % | 18.3 | 15.8 | 14.0 | |||
Current ratio | x | 1.4 | 1.3 | 1.3 | |||
Inventory Days | Days | 16 | 31 | 58 | |||
Debtors Days | Days | 9 | 10 | 9 | |||
Net fixed assets | Rs m | 70,070 | 85,653 | 95,931 | |||
Share capital | Rs m | 9,946 | 11,859 | 11,933 | |||
"Free" reserves | Rs m | 46,103 | 55,107 | 55,802 | |||
Net worth | Rs m | 56,049 | 66,966 | 67,735 | |||
Long term debt | Rs m | 23,392 | 26,221 | 33,835 | |||
Total assets | Rs m | 107,561 | 127,172 | 144,365 | |||
Interest coverage | x | 6.8 | 3.4 | 0.7 | |||
Debt to equity ratio | x | 0.4 | 0.4 | 0.5 | |||
Sales to assets ratio | x | 0.6 | 0.5 | 0.5 | |||
Return on assets | % | 9.3 | 4.5 | 1.1 | |||
Return on equity | % | 14.9 | 5.6 | -2.8 | |||
Return on capital | % | 14.0 | 7.3 | 2.2 | |||
Exports to sales | % | 0 | 0 | 0 | |||
Imports to sales | % | 0 | 0 | 0 | |||
Exports (fob) | Rs m | 0 | 0 | 0 | |||
Imports (cif) | Rs m | 0 | 0 | 0 | |||
Fx inflow | Rs m | 0 | 0 | 20,478 | |||
Fx outflow | Rs m | 0 | 0 | 6,734 | |||
Net fx | Rs m | 0 | 0 | 13,744 |
PIRAMAL PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 5,976 | 7,664 | 4,839 | |||
From Investments | Rs m | -44,799 | -18,121 | -13,388 | |||
From Financial Activity | Rs m | 39,768 | 7,942 | 8,178 | |||
Net Cashflow | Rs m | 1,100 | -1,768 | -320 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: Nandini Piramal | COMP SEC: Tanya Sanish | YEAR OF INC: 2020 | BSE CODE: 543635 | FV (Rs): 10 | DIV YIELD (%): - |
Read: PIRAMAL PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare PIRAMAL PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.